en
svPress releases
Press release 2024-09-19
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Regulatory press release 2024-08-07
Interim Report Second Quarter 2024
Regulatory press release 2024-07-26
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
Regulatory press release 2024-07-09
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
Regulatory press release 2024-05-31
New number of shares and votes in Xspray Pharma after TO6
Press release 2024-05-24
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
Regulatory press release 2024-05-21
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024
Regulatory press release 2024-05-20
Xspray Pharma appoints Chief Operating Officer and changes the Management Team
Regulatory press release 2024-05-08
Interim Report First Quarter 2024
Regulatory press release 2024-05-03